Inflammation within the CNS is a major component of many neurodegenerative diseases. A characteristic feature is the generation of microglia-derived factors that play an essential role in the immune response. IL-1b is a pro-inflammatory cytokine released by activated microglia, able to exacerbate injury at elevated levels. In the presence of caspase-1, pro-IL-1b is cleaved to the mature cytokine following NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome activation. Growing evidence suggests that ceramide plays a critical role in NLRP3 inflammasome assembly, however, the relationship between ceramide and inflammasome activation in microglia remains unknown. Here, we investigated potential mechanistic links between ceramide as a modulator of NLRP3 inflammasome assembly and the resulting secretion of IL-1b using small bioactive enzyme stimulators and inhibitors of ceramide signaling in wild-type and apoptosis-associated speck-like protein containing a CARD knockout (ASC À/À ) primary microglia. To induce the
expression of inflammasome components, microglia were primed prior to experiments. Treatment with sodium palmitate (PA) induced de novo ceramide synthesis via modulation of its synthesizing protein serine palmitoyl transferase resulting in increased IL-1b secretion in microglia. Exposure of microglia to the serine palmitoyl transferase-inhibitor L-cycloserine significantly prevented PA-induced IL-1b secretion. Application of the ceramide analogue C2 and the sphingosine-1-phosphate-receptor agonist Fingolimod (FTY720) up-regulated levels of IL-1b and cleaved caspase-1 in wild-type microglia, whereas ASC À/À microglia were unaffected. HPA-12 inhibition of ceramide transport did not affect inflammasome activation. Taken together, our findings reveal a critical role for ceramide as a positive modulator of NLRP3 inflammasome assembly and the resulting release of IL-1b. Keywords: ASC, Caspase-1, ceramide, IL-1b, microglia, NLRP3 inflammasome. J. Neurochem. (2017) 143, 534--550.
Inflammation within the central nervous system (CNS) represents a common denominator driving the progression of multiple neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (Block and Hong 2005; Heneka et al. 2014) . There are several cell types that have been linked to the modulation of inflammation-mediated neurodegeneration, but the activation of microglia has been widely accepted to play a key role in the initiation and maintenance of inflammatory conditions. As resident immune effector cells of the CNS microglia are generally considered as specialized immune surveillance cells that play a crucial role in mediating brain homeostasis and the innate immune response against a wide range of pathogenic factors (Hanisch and Kettenmann 2007) . Under inflammatory conditions microglia undergo transformation and initiate a range of host defense mechanisms, including up-regulation of a myriad of inflammatory mediators such as pro-and anti-inflammatory cytokines/chemokines (Hanisch and Kettenmann 2007; Ransohoff and Perry 2009) . In general, inflammation represents a physiological response to infections or sterile tissue damage which aims at the antimicrobial defense and induces the process of tissue healing. However, uncontrolled activation and dysregulated secretion of inflammatory mediators from excessively activated microglia can cause damage itself and in the case of neurodegenerative disease contributes to neuronal dysfunction and damage (Block and Hong 2005) . Cytokines are primary mediators of inflammatory processes within the CNS and thus represent an attractive therapeutic target for the treatment of neurological disorders. The most extensively studied cytokine is the pro-inflammatory interleukin-1b (IL-1b), which has been linked to various disorders of the CNS that are associated with inflammatory processes, including AD, Parkinson's disease, and multiple sclerosis (Allan et al. 2005; Lucas et al. 2006; Simi et al. 2007; Heneka et al. 2015) . Experimental studies of AD in mice revealed increased levels of IL-1b secretion from bamyloid activated microglia (Griffin et al. 1998; Ranaivo et al. 2006) , whereas exogenous administration or overexpression of an IL-1 receptor antagonist exerted neuroprotective properties (Relton and Rothwell 1992; Betz et al. 1995; Vezzani et al. 2000; Tehranian et al. 2002) . In vitro, IL-1b is synthesized by microglia as a precursor in response to pathogen-associated molecular patterns such as lipopolysaccharide (LPS) that is acting via Toll-like receptor activation (Takeuchi and Akira 2010; Luheshi et al. 2012) . This step, which is referred as 'priming' is required prior to the actual release of IL-1b (Bauernfeind et al. 2009; Franchi et al. 2009 ). The secretion of mature and bioactive IL-1b from primed cells depends upon the formation and activation of cytosolic multiprotein complexes called inflammasomes (Lamkanfi and Dixit 2012; Liu et al. 2013; Guo et al. 2015) . NOD-like receptor pyrin domain containing 3 (NLRP3) activation in microglia also requires a priming step and activation step in vitro (Halle et al. 2008) . After triggering of NLRP3 by danger-associated molecular patterns (DAMPs) it recruits apoptosis-associated speck-like protein (ASC), which assembles into helical fibrils and in turn recruits pro-caspase-1 causing its activation to form mature caspase-1 (Fig. 1a) . Caspase-1 then processes the precursor pro-IL-1b to its mature IL-1b form that is rapidly secreted (Brough and Rothwell 2007) . There are multiple structurally diverse pathogen-associated molecular patterns and DAMPs that have been reported to induce inflammasome activation via endogenous signaling pathways. One group of endogenous signals causing NLRP3 activation are suggested to be saturated fatty acids like palmitate and its breakdown product ceramide (Vandanmagsar et al. 2011; Wen et al. 2011) . Ceramide is a sphingosine-based lipid signaling molecule that has been linked to numerous pathophysiological processes within the CNS including neurodegeneration and elevated inflammation (Bieberich 2012) . In AD brains ceramide levels have been found to be largely increased compared to age-matched controls (Han et al. 2002; He et al. 2010) . There are multiple metabolic pathways resulting in ceramide generation; however, most studies focused on the de novo pathway and sphingomyelinase pathway (Fig. 1a) . The de novo synthesis of ceramide is generated by an enzymatic cascade commencing with the condensation of palmitoyl CoA and serine via serine palmitoyl transferase (SPT), 3-ketodihydrosphingosine reductase, dihydroceramide synthases, and dihydroceramide desaturase (Menaldino et al. 2003) . On the other hand, ceramide can be generated via sphingomylinase from the hydrolysis of sphingomyelin, a sphingolipid found in animal cell membranes, especially in the myelin sheath that surrounds CNS neurons (Marchesini and Hannun 2004) . Recently, ceramide has been reported to promote stabilization of Toll-like receptor 4 and therefore enhance LPS-induced proinflammatory signaling (Pł ociennikowska et al. 2015) . In bone-marrow-derived macrophages ceramide has been demonstrated to induce caspase-1 cleavage and IL-1b secretion in an NLRP3-dependent manner (Vandanmagsar et al. 2011) .
Here, we investigated potential mechanistic links between ceramide as a possible modulator of NLRP3 inflammasome assembly. We studied the effect of small bioactive enzyme stimulators and inhibitors of signaling mechanisms mediated by ceramide, further referred as 'ceramide signaling'. Western blot analysis, IL-1b ELISA, and immunocytochemical stainings were used as suitable readouts to detect NLRP3 inflammasome activation in primary microglia from wildtype (WT) mice and ASC À/À primary microglia as negative control for inflammasome assembly. We present evidence that ceramide helps inflammasome assembly. In WT microglia we found clear evidence for inflammasome assembly, including increased caspase-1 cleavage, an amplified release of mature IL-1b, and ASC speck formation upon stimulation of ceramide signaling, whereas microglia from ASC À/À mice were lacking these effects. Taking together, our cell culture results support a concept of ceramide as intracellular modulator of NLRP3 inflammasome assembly followed by the release of increased levels of the proinflammatory cytokine IL-1b. 
Methods

Materials
All substances were obtained from Sigma (Taufkirchen, Germany) unless otherwise stated.
Cell culture
All animals used for cell isolation were treated according to the legal and ethical requirements of the University of Bonn -Medical Center (Germany). Mouse breeding and husbandry was approved by the veterinary office (Bonn, Germany) according to the German animal welfare act. The procedures complied with the guidelines of animal welfare as laid down by the German Research Council (DFG). Primary microglia cells were isolated by the method of (Giulian and Baker 1986) . Briefly, brains from neonatal (p0-p2, mixed gender cultures) C57BL/6 WT (purchased from Charles River Laboratories Inc., Wilmington, MA, USA, RRID: IMSR_JAX:000664) and ASC À/À (purchased from Millenium Pharmaceuticals, Cambridge, MA, USA) mice were stripped of the meninges and dissociated using mechanical shearing and trypsin. Cells of two brains were plated on poly-L-lysine coated T75 culture flasks (Greiner Bio-One, Kremsm€ unster, Austria) and cultivated in Dulbecco's modified Eagle's medium (DMEM) (Gibco by Thermo Fischer Scientific, Waltham, CA, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco) and 1% penicillin/streptomycin (P/S; Gibco). On the next day cells were washed three times with Dulbecco's Phosphate Buffered Saline (DPBS) (Gibco) to remove cellular debris and cultured with DMEM supplemented with 10% FCS, 1% P/S and 1% L929 conditioned medium as a source of growth factors. After 7-10 days loosely attached mature microglia were shaken off the astrocytic monolayer with a repetition of the harvesting procedure all two to 3 days for up to three times.
Measurement of IL-1b secretion
Ceramide induction and NLRP3 inflammasome assembly were determined by measuring the IL-1b secretion using the mouse IL-1 beta/IL-1F2 DuoSet ELISA (R&D Systems, Minneapolis, MN, USA). Primary microglia (7.5 9 10 4 cells/ well) were seeded into 96-well plates and allowed to adhere overnight in DMEM supplemented with 10% FCS and 1% P/ S. On the next day medium was changed to serum-free DMEM complemented with 1% N-2 supplement (Gibco) and microglia were allowed to rest for another 24 h. Microglia were primed 3 h prior to experiments with 100 ng/mL lipopolysaccharide (LPS; InvivoGen, San Diego, CA, USA) before cells were treated with chemical compounds. C2 ceramide and FTY ((S)-FTY720 phosphate) were dissolved in dimethylsulfoxide as 25 mM and 0.5 mM stock, respectively. PA (sodium palmitate) was dissolved as 1 mM stock in sodium chloride (final conc. 0.75 mM) together with fatty acid-free bovine serum albumin (BSA, final conc. 0.17 mM; Millipore, Billerica, MA, USA) as a carrier protein, and (R,R) HPA-12 and (R,S) HPA-12 (kind gift from Dusan Berkes, Slovak University of Technology) were dissolved in EtOH as 2.5 mM stock. Supernatants were assayed after 6 and 24 h treatment according to the manufacturer's protocol. Optical density was determined at 450 nm photometrically with a microplate reader (Infinite M200; Tecan, M€ annedorf, Switzerland). Concentrations of IL-1b secretion were calculated by interpolation using an IL-1b standard curve.
Cell viability/cytotoxicity assay Cell viability of primary microglia was quantified using the XTT Cell Viability Kit (Cell Signaling Technology â , Danvers, MA, USA). Microglia from ELISA experiments were washed once with DPBS and incubated for one to 2 h with phenol red-free DMEM (Gibco) supplemented with XTT Reagent and Electron Coupling Solution according to In vitro, cells must be primed to induce the expression of inflammasome components and the precursor pro-IL-1b. The NLRP3 inflammasome consists of the pattern recognition receptor NLRP3 which recruits apoptosis-associated speck-like protein (ASC) and pro-caspase-1 upon detection of danger signals. A second signal is requires to activate the inflammasome by caspase-1 cleavage. The activated inflammasome subsequently processes the pro-IL-1b to its mature form. Here, we performed manipulation of the ceramide signaling pathway by chemical agents. Sodium palmitate (PA) has been used to induce de novo ceramide synthesis by activation of the protein serine palmitoyl transferase (SPT), whereas L-cycloserine (LCS) inhibits SPT. Exogenous ceramide levels were regulated by the ceramide analogue C2. Fingolimod (FTY720) was used as Sphingosine-1-phosphate analogue. To block the conversion of ceramide to Sphingomyelin we used HPA-12 as selective inhibitor. (b and c) The stimulatory and inhibitory impact of chemical components on the modulation of intracellular ceramide levels has been demonstrated by dot blot analysis. Dot blots were scanned and mean signal intensities of ceramide were normalized to the respective GAPDH signal. Data are mean AE SEM of six independent experiments (n = 6) with two replicates per assay (N = 12). (d) High magnification of wild-type (WT) microglia revealed the absence of ASC-immunoreactivity under basal conditions. (e) However, when lipopolysaccharide was used as a tool to prime the inflammasome, ASC-immunoreactive accumulations were found inside the cytoplasm of WT microglia. ASC À/À microglia were lacking ASC-immunoreactivity under basal conditions (f) and primed conditions (g). A total of at least 250 cells were checked for ASCimmunoreactivity and five randomly chosen cells were examined at high magnification. Green: CD11b; Red: ASC; Blue: DAPI. Scale bar 20 lm. the manufacturer's protocol. Absorbance was measured at 450 nm with a microplate reader. To assess cytotoxicity of chemical compounds the cytotoxicity detection kit (LDH) (Roche, Mannheim, Germany) was used. 50 lL of cell supernatants from ELISA experiments was used to perform the cytotoxicity assay according to the manufacturer's protocol. Absorbance was measured at 450 nm with a microplate reader.
Precipitation of supernatant samples
For detection of the cleaved caspase-1 subunit p20 in the supernatant of treated primary microglia cultures we performed a protein precipitation to concentrate the sample as described by (Jakobs et al. 2013) . Briefly, primary microglia (1.5 9 10 6 in 2 mL medium) were cultured for 24 h in 6-well plates under control conditions or in medium containing chemical compounds. After harvesting the supernatants 500 lL methanol and 125 lL chloroform were added to 500 lL supernatant and vortex vigorously. After 5 min centrifugation at 13 000 g the upper aqueous phase was removed and replaced by 500 lL methanol. Samples were vortex vigorously and centrifuged for 5 min at 13 000 g. Supernatant was removed and pellet was dried for 5 min in a vacuum dryer. The pellet was then resuspended in 20 lL 29 Loading Buffer and denaturated for 3 min at 95°C. Samples were then subjected to western blot analysis.
Immunoblotting
For lysate collection, primary microglia (1.5 9 10 6 ) were cultured in 6-well plates under control conditions or in medium containing chemical compounds for 6 h (dot blot) or 24 h (western blot) before supernatants (for protein precipitation) were collected and cells were washed and scraped off the well with ice cold phosphate-buffered saline (PBS) containing 19 protease inhibitor cocktails. After pelleting the cells for 5 min at 10 000 g PBS was completely removed and cells were lysed in ice cold ristocetin-induced platelet agglutination buffer (50 mM Tris-HCl, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% sodium dodecyl sulfate, 150 mM NaCl, pH 8.0) containing 19 protease inhibitor cocktails for 15 min on ice. Lysates were centrifuged 5 min at 4°C and 10 000 g and supernatants were frozen and kept in À20°C until use.
Cell lysates and samples from protein precipitation were separated by a NuPAGE (1 : 10 000 in 3% BSA; LI-COR Biotechnology, Lincoln, NE, USA, RRID: AB_1850025) and IRDye â 680LT Goat anti-Mouse IgG (H + L) (1 : 10 000 in 3% BSA; LI-COR Biotechnology, RRID: AB_2687826) were applied for 30 min at 25°C. Proteins were then visualized with the Odyssey CLx Imaging System (LI-COR Biosciences, Lincoln, NE, USA) and quantified using Image Studio (LI-COR Biosciences). For dot blot analysis, 2 lL of sample lysates was spotted onto a nitrocellulose membrane (0.2 lm) and processed as described above. Membranes were incubated with mouse anti-ceramide antibody (1 : 50; MID 15B4; Enzo Life Sciences, L€ orrach, Germany, RRID: AB_2051116) and rabbit anti-GAPDH (1 : 500, RRID: AB_10610160) for 3 h at 25°C. Membranes were incubated with secondary antibodies and samples were visualized as described above.
Immunocytochemistry
Cultures were fixed in 4% paraformaldehyde dissolved in PBS (Biochrom GmbH, Berlin, Germany) for 15 min and permeabilized by washing them tree times for 5 min with PBS containing 0.1% Triton X-100 (PTX). Blocking solution containing PTX and 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA, RRID: AB_2336615) was applied for 30 min. The primary antibodies rabbit anti-ASC (1 : 250; clone AL177, RRID: AB_2490440) and rat anti-CD11b (1 : 250; Serotec by Bio-Rad, Hercules, CA, USA, RRID: AB_323167) were applied for 1 h followed by three washing steps. The secondary antibodies goat anti-rabbit (1 : 250; Invitrogen, RRID: AB_143165) and goat anti-rat (1 : 250; Invitrogen, RRID: AB_141374) were applied for 30 min. 4 0 ,6-diamidino-2 0 -phenylindol-dihydrochloride (DAPI) was used for nuclear counter-staining at 0.1 mg/mL for 20 min in PBS. Images were taken using a 609 oil-objective.
Microscopy
All experiments were examined with a Nikon Eclipse Ti fluorescence microscope (Nikon, Tokio, Japan). Acquired images were processed using NIS-elements 4 (Nikon) and Fiji ImageJ (Wayne Rusband; National Institute of Health, Bethesda, MD, USA).
Statistical analysis
Data were evaluated using Graph Pad Prism and presented as mean AE SEM of at least three independent experiments with three replicates. Data were analyzed for Gaussian distribution. When data passed the normality test statistical comparisons of vehicle controls versus treatment were performed with one-way ANOVA in conjunction with a Tukey's test. Otherwise, data were analyzed with the Kruskal-Wallis test and a Dunn's post hoc test for non-parametric data. Levels of significance are indicated as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. No blinding of the experimenter was performed in this study.
Results
To test for a potential role of ceramide as modulator of NLRP3 inflammasome assembly and the resulting secretion of mature IL-1b from primary microglia cultures, we used small bioactive enzyme stimulators and inhibitors of the ceramide signaling pathway (Fig. 1a) . We primed microglia prior to experiments to induce the expression of inflammasome components (NLRP3, ASC, and pro-caspase-1) and pro-IL-1b by LPS (100 ng/mL) treatment (Fig. 1a) . After 3 h of priming, LPS was removed and cells were exposed to chemical compounds interfering with the ceramide signaling pathway as second stimulus for either 6 or 24 h. The stimulatory and inhibitory impact of the applied chemical components on the modulation of intracellular ceramide levels has been demonstrated by dot blot analysis (Fig. 1b and c) . To confirm ASC speck formation as indicator for inflammasome assembly, we performed immunostainings against ASC and CD11b as microglia marker (Fig. 1d-g ). We found that WT microglia showed a fairly low ASC signal under basal conditions (Fig. 1d) . In contrast, LPS-priming of these cells induced ASC accumulation (Fig. 1e, dashed lines) . We detected the outgrowth of many thick processes under basal and primed conditions (Fig. 1d-g ); however, untreated microglia exhibited various microspikes at the terminations of these processes (Fig. 1d) . ASC À/À microglia lacked any specific antibody staining signal with anti-ASC Abs and their cellular morphology appeared similar to that of WT microglia ( Fig. 1d and e). Thus, priming of microglia seems to be an essential trigger for ASC clustering prior to ASC speck formation and inflammasome activation via a second stimulus.
Ceramide signaling induce ASC expression and speck formation ASC has been shown to be an essential component of inflammasomes. Following inflammasome activation, ASC assembles into a large protein complex termed 'ASC speck' via dimerization and oligomerization steps (Fig. 2) . Upon NLRP3 inflammasome activation the majority of inflammasome components (NLRP3, ASC, and pro-caspase-1 p45) have been described to be released into the cell supernatant to may activate surrounding cells (Baroja-Mazo et al. 2014) . For this reason we subjected cell lysates and supernatants to western blot analysis and check for the presence of inflammasome components in both. Here, we visualized ASC expression and oligomerization via western blot analysis and immunocytochemical staining following stimulation of ceramide signaling in WT microglia (Fig. 2) .
Chemical compounds used for this study are described more in detail in the following sections. We used the ceramide analogue C2 and the sphingosine-1-phosphate-repector (S1PR) agonist Fingolimod (FTY720) to induce ceramide signaling (Fig. 1a) . Both substances largely increased the expression of monomeric ASC in a dose-dependent manner ( Fig. 2a and b) . Moreover, we found ASC dimerization and oligomerization in the lysate of microglia, indicating inflammasome activation (Fig. 2a) . Large amounts of extracellular ASC-monomers were found in the supernatants of microglia treated with C2 and FTY720 ( Fig. 2a and b) . Next, we used two different enantiomers of HPA-12 as selective inhibitors of ceramide transport processes (Fig. 1a and Figure S2 ). Neither (R,S) HPA-12 nor (R,R) HPA-12 did change the level of ASC expression in cell lysates and cell supernatants compared to the primed control ( Fig. 2c and d) .
In addition to western blot analysis, we performed immunocytochemical stainings to visualize ASC speck formation (Fig. 2e) . Indeed, stimulation of ceramide signaling via C2 and FTY720 induced the formation of ASC specks as visualized by around 1 lm ASC-immunoreactive puncta inside the cytoplasm of the cells (Fig. 2e) . Similar effects were observed when LPS-primed microglia were treated with sodium palmitate (PA) to induce de novo ceramide synthesis (Fig. 2e) . Co-application of the de novo synthesis inhibitor L-cycloserine slightly decreased the number of ASC speck positive microglia (Fig. 2f) . Quantification of ASC speck formation showed that substances that stimulate ceramide signaling (Fig. 1a) significantly induced specking of ASC (p < 0.0001), whereas ceramide transport blockers (Fig. 1a ) had no effect on ASC speck formation compared to the control ((R,R) HPA-12, p = 0.573; (R,S) HPA-12, p = 0.302) (Fig. 2f) . In addition to an increased number of ASC speck positive microglia (Fig. 2f) , the number of ASC specks per cell was increased following induction of ceramide signaling (Fig. 2g) compared to the control. Thus, our data suggest that ceramide signaling plays an essential role in ASC speck formation that is necessary for inflammasome activation.
Ceramide de novo synthesis induces IL-1b secretion in primary microglia Initially, we tested whether de novo ceramide synthesis could affect IL-1b secretion in primary microglia by modulation of the ceramide synthesizing protein SPT. Treatment with the SPT activator PA did not cause any changes in IL-1b secretion within 6 h of treatment. Coincident with this, co-application of PA and the SPT inhibitor LCS had no effect on the IL-1b release compared to the BSA vehicle control (Fig. 3a) . LPS-primed WT microglia showed an increased basal release of IL-1b that was further increased in response to BSA (Fig. 3a) . 24 h treatment with PA led to a slightly increased IL-1b secretion in comparison to its BSA control. Co-application of PA and LCS significantly decreased the PA-induced IL1b secretion (Fig. 3a) . Microglia isolated from ASC À/À mice were not able to release appreciable levels of IL-1b upon the different treatments. Co-application of PA and LCS decreased the IL-1b release in both cases (p < 0.001, PA-treated vs. PA + LCS-treated cells). and (e) XTT-readings were performed to check for microglial healthiness. PA and PA + LCS significantly induced LDH release (n = 4) from microglia, whereas the metabolic activity (n = 4) was largely decreased indicating the induction of cell death processes. Data are mean AE SEM of at least three independent experiments with three replicates per condition [*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 compared to its respective vehicle control (black bars)]. Green: CD11b; Red: ASC; Blue: DAPI. Scale bar 20 lm. lm ASC-immunoreactive puncta (ASC specks) inside the cytoplasm of microglia treated with ceramide signaling stimulating drugs. (f and g) Quantification of ASC speck formation in microglia showed that not only the number of ASC speck positive microglia was largely increased (n = 3, N = 18) (f) but also the number of ASC specks per cell (at least 250 cells were examined per condition) (g) has changes upon treatment with components interfering with the ceramide signaling pathway. Data are mean AE SEM of at least three independent experiments (****p < 0.0001 compared to its control). Red: ASC; Blue: DAPI. Scale bar 20 lm.
To visualize effects of PA on cell morphology and NLRP3 inflammasome assembly, we performed immunostainings against the microglia marker CD11b and the inflammasome component ASC (Fig. 3b and c) . High magnifications of PAtreated WT microglia that survived pyroptosis following inflammasome activation (10-15% of total microglia) revealed the retraction of cellular processes, which were found under primed conditions (Fig. 1e) . PA-induced cellular morphology was characterized by various microspike projections around the soma (Fig. 3b) . Three-dimensional analyses (x-, y-, and zaxis) of PA-treated cells indicated the presence of ASC specks inside the cytoplasm (Fig. 3b, dashed lines) . Co-application of PA and LCS promoted slight morphological changes causing a switch from various microspike projections to a more round and ameboid shape (Fig. 3c) . Similar morphological changes were detected when primary ASC À/À microglia were treated with PA or PA + LCS ( Figure S1a and b) ; however, ASCimmunoreactivity was completely absent in these cells ( Figure S1a and b) .
Using the LDH-assay we measured LDH release from microglia as marker for cytotoxicity. Application of PA did not change the LDH release after 6 h of treatment; however, 24 h of treatment almost doubled the LDH release in WT and ASC À/À microglia (Fig. 3d) . Co-treatment with LCS did not reverse the PA-induced LDH release. These results are in line with results quantifying the metabolic activity of the cells as indirect marker for cell viability. Using the XTT-assay we found that PA-treatment resulted in decreased cell viability after 6 and 24 h which was slightly but not significantly reversed by co-application of LCS (Fig. 3e) . Taking together, these data indicate that de novo synthesis of ceramide modulates NLRP3 inflammasome assembly and IL-1b secretion in primary microglia.
Exogenous application of ceramide stimulates IL-1b secretion Next, we asked whether the application of the cell permeable short chain ceramide analogue C2 could affect the NLRP3 inflammasome assembly and IL-1b release in our cultures. Indeed, treatment of microglia with C2 resulted in an increased release of IL-1b in a time-and dose-dependent manner as measured by ELISA readings, whereas C2 did not cause any changes in IL-1b release in ASC À/À microglia (Fig. 4a) . Application of C2 did not cause any morphological changes in cells that survived C2 treatment (Fig. 4b ) compared to control cells (Fig. 1e) , but showed the accumulation of ASC-immunoreactive aggregates inside the cytoplasm of microglia (Fig. 4b, dashed lines) . Primary ASC À/À microglia showed similar morphological shapes when treated with the ceramide analogue C2 ( Figure S1c) ; however, we could not detect any ASC-immunoreactivity in this cells ( Figure S1c ). Caspase-1 has been described as IL-1b-converting enzyme that cleaves pro-IL-1b to the mature cytokine (Fig. 1a) . In the absence of an activated inflammasome caspase-1 is primarily detectable as pro-caspase-1 (p45) in the cell lysate; however, the activation of the inflammasome causes proteolytical cleavage. Cleaved caspase-1 subunits (p20 and p10) can be detected in the cell lysate at the earlier stage of activation, but are secreted to the supernatant at about 15 min after activation. Here, we examined caspase-1 cleavage following C2 treatment by western blot analysis using antibodies raised against pro-caspase-1 (p45) and the cleaved subunit p20 in the cell lysate and cell supernatant of WT (Fig. 4c) and ASC À/À microglia (Fig. 4d) . Treatment of microglia with C2 raised the intracellular level of cleaved p20 subunit about 12-fold (at 25 lM), whereas the level of p20 was increased 24-fold (at 25 lM) in the supernatant compared to controls (Fig. 4e) . Levels of the housekeeping gene a-tubulin were notably inconsistent in the cell lysates throughout the different conditions, whereas a-tubulin levels became detectable in cell supernatants indicating cellular damage. Even though there are inconsistencies in the intracellular protein levels, one has to keep in mind that the secretion of inflammasome components (e.g., ASC and caspase-1 p20) and thus the detection of these components in the supernatant is the main characteristic of inflammasome activation. Consistent with our ELISA results (Fig 3a) caspase-1 cleavage was not detectable in the cell lysate and supernatant of ASC À/À microglia, respectively (Fig. 4d) .
Concentrations between 10 and 25 lM increased the release of LDH (Fig. 4e) , whereas the metabolic activity was decreased dose-dependently (Fig. 4f) as already indicated by a-tubulin detection in the cell supernatant ( Fig. 4c and d) . ) microglia IL-1b secretion was completely absent in response to C2 (n = 4). (b) When wild-type (WT) microglia were treated with C2 accumulation of ASC-immunoreactive aggregations were found inside the cells (dashed lines; five randomly chosen cells were examined at high magnification). (c) Western blot analysis showed that treatment of microglia with C2 raised the intracellular level of the cleaved subunit p20 about 12-fold, whereas the extracellular level of p20 was increased 24-fold (n = 4). (d) Caspase-1 cleavage was completely absent in ASC À/À microglia (n = 3). (e) Lactate dehydrogenase (n = 4) release was increased in both genotypes (f), whereas the metabolic activity (n = 4) was largely decreased. Data are mean AE SEM of at least three independent experiments with three replicates per condition [*p < 0.05; **p < 0.01; ****p < 0.0001 compared to its respective vehicle control (black bars)]. Green: CD11b; Red: ASC; Blue: DAPI. Scale bar 20 lm.
Fingolimod (FTY720) induces IL-1b secretion and apoptosis in microglia Ceramide has been described as a central molecule in sphingolipid structure and metabolism with multiple routes of intracellular signaling (Fig. 1a) including conversion into the ceramide related lipid S1P via Sphingosine (Sph). Here, we used FTY720 as a potent agonist of the S1P-repector (S1PR) to activate S1P signaling and its signaling metabolite Sph. Using the S1P analogue Fingolimod (FTY720) at concentrations up to 10 lM, we determined the effects of S1P signaling on maturation of IL-1b (Fig. 5a ). We found that FTY720 induced the IL-1b release in WT microglia after 6 and 24 h significantly in a time-and dose-dependent manner up to 859.8 AE 92.35 pg/mL and 2499.1 AE 311.5 pg/mL at 10 lM, respectively (Fig. 5a ). In contrast, treatment of ASC À/À microglia with FTY720 did not induce any IL-1b release (Fig. 5a ). FTY720-treatment of microglia did not cause any striking morphological changes in microglia treated with FTY720 ( Fig. 5b ) as compared to control cells (Fig. 1e) , but showed ASC-labeled intracellular accumulations (Fig. 5b, dashed lines) . Similar morphological shapes were detected when primary ASC À/À microglia were treated with FTY720, but cells were lacking ASC accumulation ( Figure S1d ). Culturing microglia for 24 h with FTY720 (5 and 10 lM) caused a decreased level of the cleaved caspase-1 subunit p20 in the cell lysate, whereas its abundance was increased in cell supernatants (Fig. 5c) . Similar results were found by examining the presence of the pro-caspase-1 (p45). Moreover, we found that extracellular level of a-tubulin (as detected in supernatant) was increased in FTY720-treated cells indicating that cells undergo cell death, which is in line with our result regarding the relative metabolic activity (Fig. 5f ). Treating WT and ASC À/À microglia with FTY720
largely induced the release of LDH at concentrations between 2.5 and 10 lM in a dose-dependent manner (Fig. 5e) , whereas in parallel the metabolic activity was dose-dependently reduced by about~75% at 10 lM FTY720 (Fig. 5f ). Taking together, these results suggest that high doses of FTY720 act on LPS-primed microglia by activating NLRP3 inflammasomes to induce the secretion of IL-1b.
Inhibition of ceramide transport showed no effects on IL-1b secretion To uncover the effects of the conversion of ceramide to sphingomyelin on NLRP3 inflammasome activation we used HPA-12 as selective inhibitor of the ceramide transport protein (CERT) ( Figure S2 ) (Mencarelli and Martinez-Martinez 2013) . We tested both, the (R,R) HPA-12 and (R,S) HPA-12 enantiomer using IL-1b ELISA readings and western blot analysis as readouts for inflammasome activation (Fig. 6) . By quantifying the impact of (R,R) HPA-12 on IL-1b secretion we found that neither WT nor ASC À/À microglia were affected at concentrations between 1 and 10 lM compared to its respective vehicle controls (Fig. 6a) . In contrast, the application of (R,S) HPA-12 did increase IL-1b release in WT microglia significantly up to 19.14 AE 3.33 pg/mL compared to its vehicle control (3.78 AE 0.64 pg/mL) (Fig. 6b) . However, these effects were no longer significant after 24 h of treatment. IL-1b secretion in ASC À/À microglia did not increase above the baseline of the assay. Immunocytochemical analyses revealed that cellular morphology of (R,R) HPA-12 and (R,S) HPA-12-treated cells slightly changed from cells with many thick processes (Fig. 1e) to a more spindle-shaped phenotype with some tiny microspikes ( Fig. 6c and d) . Treatment of both HPA-12 analogues caused the assembly of ASC-specks in the cytoplasm of the cells ( Fig. 6c and d, dashed lines) .
We performed western blot analysis to check for caspase-1 cleavage in HPA-12-treated cells. Incubation with (R,R) HPA-12 as well as (R,S) HPA-12 did not cause any changes in the level of caspase-1 cleavage ( Fig. 6e and f) as evaluated in cell lysate and supernatant of WT (Fig. 6e) and ASC À/À (Fig. 6f) microglia. We performed LDH and XTT measurements to check for cytotoxic effects of both HPA-12 components. Neither (R,R) HPA-12 nor (R,S) HPA-12 did cause any striking changes with regard to the LDH release (data not shown). However, we found that 10 lM of both compounds slightly reduced the metabolic activity of WT and ASC À/À microglia by 10-15% compared to its respective vehicle control (data not shown).
Discussion
Many studies have concluded that the bioactive sphingolipid metabolite ceramide regulates a number of physiological processes closely associated with inflammation and neurodegenerative disorders such as AD (Smith et al. 2012; Mencarelli and Martinez-Martinez 2013; Wang et al. 2015) . However, little is known about the biological relevance of ceramide in microglia. Our present investigation helps to unravel whether ceramide metabolism can regulate inflammasome assembly and the secretion of proinflammatory IL-1b in murine primary microglia. The À/À microglia caspase-1 cleavage was absent in FTY720-treated cells (n = 3). Application of FTY720 did increase the lactate dehydrogenase release (n = 4) in both genotypes dose-dependently (e), whereas the metabolic activity (n = 4) was largely decreased in a similar pattern (f). Data are mean AE SEM of at least three independent experiments with three replicates per condition [*p < 0.05; **p < 0.01; ****p < 0.0001 compared to its respective vehicle control (black bars)]. Green: CD11b; Red: ASC; Blue: DAPI. Scale bar 20 lm.
activation of mature caspase-1 and the subsequent release of IL-1b from cells require two concomitant signals ( Fig. 1 ; Wen et al. 2011) . While the first 'priming' signal is necessary to induce the expression of inflammasome components such as ASC, pro-caspase-1 and pro-IL-1b, a second signal is required to activate the assembly of the multi-protein complex to form the inflammasome resulting in the cleavage of pro-caspase-1 to caspase-1 and the maturation of IL-1b (Fig. 1a) . Here, we used LPS as an adequate in vitro activation agent to 'prime' inflammasomes (Vandanmagsar et al. 2011; Wen et al. 2011; Tracy et al. 2013; Gustin et al. 2015) prior to chemical manipulation of ceramide signaling as second signal (Fig. 1a-c) . Indeed, 'priming' of microglia resulted in the expression of ASC which is necessary for inflammasome formation (Figs 1d,e and 2), whereas 'priming' did not induce inflammasome formation in ASC À/À microglia ( Fig. 1d and e) . We found that priming of WT microglia with LPS elevated the release of IL-1b within 24 h (but not 6 h) upon priming without any further activation (Figs 3a and 6a) . LPS has been shown to act as priming agent to stimulate the expression of inflammasome component precursors including pro-caspase-1 and pro-IL-1b. However, one has to keep in mind that LPS treatment of microglia did not just prime the NLRP3 inflammasome but also activate various other inflammatory pathways (Kim et al. 2004) . Thus, it is likely that the activation of other inflammatory pathways act as second stimulus in the process of inflammasome activation to a certain circumstance.
To quantify the effects of ceramide signaling on microglial NLRP3 inflammasomes we used immunocytochemistry, ELISA readings and western blot analysis as suitable readouts.
Ceramide stimulates caspase-1 cleavage and IL-1b secretion There is growing evidence that the release of cytokines following microglial activation is one major factor contributing to excessive inflammatory responses causing eventually complete neurodegeneration (Block and Hong 2005; Block et al. 2007; Ransohoff and Perry 2009; Heneka et al. 2013 Heneka et al. , 2014 Heneka et al. , 2015 . In brains of AD patients ceramide levels have been consistently reported to be about three times higher compared to age-matched controls (Han et al. 2002; Cutler et al. 2004; He et al. 2010; Geekiyanage and Chan 2011) and interestingly, the ceramide transporter CERT has been identified in amyloid plaques (Mencarelli et al. 2012) . Thus, elevated ceramide levels may play an important role in neurodegeneration. However, the molecular interrelationship between ceramide and neurodegeneration are not completely understood yet.
Using the common saturated fatty acid PA as activator of SPT (Patil and Chan 2005; Patil et al. 2007; Liu et al. 2013) and LCS as inhibitor (Liu and Chan 2014) , we determined the effects of de novo ceramide synthesis on inflammasome activation and cytokine secretion in microglia (Fig. 1a) . Interestingly, we found that sole application of the carrier protein BSA already increased the release of IL-1b from LPS-primed microglia even in the absence of PA (Fig. 3a) . Exposure of microglia to albumin has been shown to increase the release of IL-1b and NO following activation of all three MAPK pathways (Ranaivo and Wainwright 2010) . Stimulation of SPT induced the IL-1b secretion in WT microglia within 24 h (but not 6 h) (Fig. 3a) which was not significantly different compared to its respective BSA control. However, since BSA alone has been shown to induce IL-1b secretion from microglia it is likely that the BSA-induced IL-1b release overwhelm the effects of PA. In general, de novo sphingolipid synthesis has been shown to be critical for regulating ceramide levels and the subsequent release of inflammatory cytokines (for review see : Hanada 2003) . Previous reports on human monocytes (Snodgrass et al. 2013) , human bone marrow-derived macrophages (Wen et al. 2011) , and murine astrocytes (Liu et al. 2013 ) have therefore revealed PA as a powerful inducer of proinflammatory responses and the release of cytokines such as IL-1b, IL-6, and IL-18. Interestingly, disruption of PAinduced ceramide de novo synthesis by co-application of LCS significantly prevented the release of inflammatory agents (Fig. 3a) consistent with data generated in astrocytes (Liu et al. 2013) . Since the adaptor protein ASC is essential for inflammasome formation, we used primary microglia from ASC À/À mice to determine inflammasomeindependent effects of ceramide (Fig. 2) . Remarkably, we found that PA treatment slightly increased the IL-1b secretion above the baseline of the assay in ASC À/À microglia indicating that IL-1b maturation may be inflammasome-independent to a fairly small amount (Fig. 3a) . To further confirm inflammasome activation we performed immunostainings to detect essential ASC speck formation in microglia (Fig. 2) (Heneka et al. 2013) . Indeed, ASCimmunoreactive aggregations formed inside PA-treated cells (Figs 2e-g and 3b,c) that was accompanied by decreased cell viability ( Fig. 3d and e) . Elevation of intracellular ceramide levels following cytotoxic accumulation of PA has been shown to induce apoptosis in various cell types (for review see : Hanada 2003) independently from inflammasome activation (Listenberger et al. 2001 ; ) (n = 3) microglia at concentrations between 1 and 10 lM. (b) In contrast, application of (R,S) HPA-12 significantly increased IL-1b release from WT microglia after 6 h (n = 4); however, this effect was no longer significant after 24 h (n = 4). (c and d) Treatment with both HPA-12 enantiomers did not disrupt the lipopolysaccharide-induced accumulation of ASC-immunoreactive puncta (as shown in Fig. 1e ). Western blot analysis showed that inhibition of ceramide transport via HPA-12 did not cause any conspicuous changes in the level of caspase-1 cleavage in WT microglia (n = 6) (e) and ASC À/À microglia (n = 3) (f). Data are mean AE SEM of at least three independent experiments with three replicates per condition [*p < 0.05; ****p < 0.0001 compared to its respective vehicle control (black bars)]. Green: CD11b; Red: ASC; Blue: DAPI. Scale bar 20 lm. Zhao et al. 2004) . Co-application of LCS did not change the number of PA-induced ASC specks indicating that PA may directly affect ASC speck formation. However, whether and how PA could affect ASC oligomerization requires further investigation.
To further support the hypothesis that ceramide can activate the NLRP3 inflammasome in microglia we applied C2 as ceramide analogue. Treatment with C2 induced the secretion of IL-1b within 6 h and amplified the release within 24 h (Fig. 4a) which was accompanied by ASC aggregate-formation (Figs 2 and 4b ). In addition, we found caspase-1 cleavage and increased levels of cleaved caspase-1 subunit p20 in the supernatant of C2-treated microglia to further confirm inflammasome activation (Fig. 4c) . Using the ceramide analogue C2 we confirmed our above stated results regarding the capacity of ceramide to activate the NLRP3 inflammasome (Fig. 3) . Moreover, these results are consistent with a study on macrophages demonstrating that C2 activates NLRP3 inflammasome (Vandanmagsar et al. 2011) .
Taking together, our findings provide evidence for a substantial role of ceramide signaling in modulating NLRP3 inflammasome activation.
Ceramide breakdown product Sph induces IL-1b secretion and apoptosis in microglia The intracellular signaling mechanisms of ceramide implicate downstream the activation of its breakdown product Sphingosine (Sph). Sph is a bioactive sphingolipid metabolite that serves as a substrate for ceramide regeneration via the salvage pathway (Maceyka and Spiegel 2014) . Under disease conditions, Sph has been described to be elevated in the brain (Dasgupta et al. 2007; He et al. 2010) and thus understanding Sph signaling could help to pinpoint ceramide and its breakdown products as targets in the treatment of excessive inflammation. To manipulate the intracellular Sph level, we used FTY720 (Fingolimod) at high doses, a well characterized S1P analogue that has been approved for the treatment of multiple sclerosis (for review see: Brinkmann et al. 2010) . Application of FTY720 did induce IL-1b secretion in our LPS-primed microglia cultures within 6 h and became more abundant after 24 h (Fig. 5a ), accompanied by ASC speck formation (Figs 2 and 5b) and caspase-1 cleavage including enriched levels of the cleaved caspase-1 subunit p20 in cell supernatants (Fig. 5c) . Similar investigations on LPS-primed murine macrophages (Luheshi et al. 2012 ) and murine astrocytes (Janssen et al. 2015) have revealed that NLRP3 inflammasome activation and the resulting IL-1b secretion is positively regulated by high doses of FTY720 acting as DAMP via ceramide signaling. Moreover, we found that FTY720 induced microglial cell death in an inflammasomeindependent manner (Fig. 5e and f) . These findings confirm our above stated results regarding the inflammasomeindependent induction of cell death pathways. Sph has been previously reported to induce apoptotic and necrotic cell death because of its ability to accumulate in lysosomes and destabilize their membrane (K agedal et al. 2001; Luheshi et al. 2012) . However, further investigations are required to elucidate the exact mechanisms and the nature of the cell death observed in FTY720-treated microglia.
Sphingomyelin did not affect secretion of microglial IL-1b The predominant source of sphingolipid metabolites, such as ceramide and sphingosine is sphingomyelin, which is located in the mammalian cell membrane. The relationship between ceramide and sphingomyelin could be described as an intracellular feedback trafficking mechanism: hydrolysis of sphingomyelin via sphingomyelinase results in an increased level of ceramide, whereas ceramide itself could be transported back to the site of sphingomyelin synthase (Fig. 1a) . Here, we used two different analogues of HPA-12, namely (R,R) HPA-12 and the more active (R,S) HPA-12, as selective inhibitors of the ceramide transport ( Figure S2 ) from the ER to the Golgi apparatus as site of sphingomyelin synthesis (Yasuda et al. 2001; Nakamura et al. 2003; Hanada et al. 2009) . Blocking CERT could then increase accumulation of ceramide in the ER ( Figure S2 ) leading to ER stress and cell death (Ponnusamy et al. 2010) . Here, we demonstrated that the more active (R,S) HPA-12 analogue increased IL-1b secretion within 6 h and appears to cause a weak dose-dependent (but not significant) tendency for increased IL-1b secretion within 24 h ( Fig. 6a and b) . Immunostainings revealed the presence of ASC specks inside HPA-12 (both analogues) treated cells which was, however, not significantly increased compared to the control (Figs 2c-g and 6c,d). In line with this, HPA-12-treated microglia were lacking caspase-1 cleavage ( Fig. 6e and f) . This absence of an effect might be explained by low levels of ceramide synthesis under primed conditions, where a second signal for NLRP3 inflammasome activation is missing. Anyway, if and whether HPA-12 analogues could have an impact on microglia during inflammatory conditions needs to be elucidated in more detail.
Conclusion
In summary, this in vitro study revealed a rather complex regulatory function of ceramide for modulating NLRP3 inflammasome assembly and activation in microglia. Treatment of microglia with agents that induce ceramide signaling increased NLRP3 inflammasome assembly and IL-1b release, whereas disruption of these signaling steps reduced inflammasome activation. These findings highlight the potential of targeting intracellular ceramide signaling mechanisms and represent an important initial step for designing novel ceramide-modulating strategies to control excessive cytokine release under inflammatory conditions in the nervous system. The authors thank Francesco Santarelli for technical assistance, as well as Dr. Simone Crivelli for chemical compound exchange between the groups. This work was supported by the EU framework program JPND to MTH (InCure). PMM was supported by grants from ZonMw Memorabel program (projectnr: 733050105) and by the international foundation for Alzheimer Research (ISAO) (projectnr: 14545). The authors declare that there is no conflict of interest with regard to the experimental part of this study. Michael T. Heneka is handling editor for the Journal of Neurochemistry.
All experiments were conducted in compliance with the ARRIVE guidelines.
Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . Morphological changes upon modulation of ceramide signaling in ASC À/À microglia. Figure S2 . HPA-12 treatment results in the inhibition of ceramide transport and ceramide accumulation immediately adjacent to the cell nucleus in microglia.
